Ricky Zipp

Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission requested more information.

CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues that have now been resolved.

The Center for Devices and Radiological Health’s pilot program is meant to cut the time between the FDA’s awareness of potentially high-risk recalls and when the public is notified.

Martin Makary, a Johns Hopkins surgeon and researcher, has been critical of the FDA. He could have the most influence over device policy among Trump’s nominees.

Acutus has now tied two large layoffs to the Medtronic partnership. In November 2023, the firm cut about 160 people to focus on requirements of the manufacturing and distribution deal.

From M&A and tariffs to new health leaders, here are the top issues for the medtech industry to watch when President-elect Donald Trump returns to office.

Nastassia Tamari discussed how compliance with new device cybersecurity requirements is going, the risks of legacy devices and frequent cyberattacks in healthcare.

Certain Accolade pacemakers can permanently enter safety mode, which limits the devices’ ability to treat patients properly and requires early replacement.

With about one month before inauguration day, check out a roundup of MedTech Dive’s coverage on what President-elect Donald Trump’s new administration means for medical device companies.

From challenging market leaders to the growing influence of artificial intelligence, medical device executives had a lot to discuss this year. Check out MedTech Dive’s top Q&As of 2024.